Diagnosis, Management Strategies for Treatment-Resistant Depression
Treatment-resistant depression (TRD) is defined—for individuals with major depressive disorder—as patients who have not made significant improvements with at least two courses of antidepressant treatment, according to Manish Jha, MBBS, who is presenting a session on diagnosing and managing TRD at Practical Updates in Primary Care 2022 Virtual Series.
“A lifetime treatment history may often have to be underscored or taken into context when we are considering the definition of TRD,” Dr Jha added.
Dr Jha is an assistant professor of psychiatry in the Center for Depression Research and Clinical Care at University of Texas Southwestern Medical Center in Austin, Texas. He is presenting a session titled, “Voter’s Choice: Diagnosis and Management of TRD in Primary Care Settings” at Practical Updates in Primary Care 2022 Virtual Series.
The learning objectives during Dr Jha’s presentation include:
- How measurement-based care tools can be implemented to monitor improvement symptoms with antidepressant treatment
- Understand how treatment-resistant depression in patients can be diagnosed in clinical practice
- Identify different strategies for managing treatment-resistant depression, including partnering with psychiatric providers
Dr Jha discusses the different strategies and tools to use when diagnosing individuals that may have TRD, and the use of ketamine and esketamine in the treatment of TRD.
For more meeting coverage, visit the Practical Updates in Primary Care newsroom.
Maximize your experience by adding up to 90-days of on-demand access! Find the package that works for you. Upgrade here.
Jha MK. Voter’s choice: diagnosis and management of treatment-resistant depression (TRD) in primary care settings. Talk presented at: Practical Updates in Primary Care 2022 Virtual Series; November 16-18, 2022; Virtual. https://www.practicalupdates.consultant360.com/